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Influenza B viruses (IBV) cause respiratory disease epidemics in humans and are therefore
components of seasonal influenza vaccines. Serological methods are employed to
evaluate vaccine immunogenicity prior to licensure. However, classical methods to
assess influenza vaccine immunogenicity such as the hemagglutination inhibition assay
(HI) and the serial radial hemolysis assay (SRH), have been proven to have many
limitations. As such, there is a need to develop innovative methods that can improve on
these traditional assays and provide advantages such as ease of production and access,
safety, reproducibility, and specificity. It has been previously demonstrated that the use of
replication-defective viruses, such as lentiviral vectors pseudotyped with influenza A
hemagglutinins in microneutralization assays (pMN) is a safe and sensitive alternative to
study antibody responses elicited by natural influenza infection or vaccination.
Consequently, we have produced Influenza B hemagglutinin-pseudotypes (IBV PV)
using plasmid-directed transfection. To activate influenza B hemagglutinin, we have
explored the use of proteases in increasing PV titers via their co-transfection during
pseudotype virus production. When tested for their ability to transduce target cells, the
influenza B pseudotypes produced exhibit tropism for different cell lines. The pseudotypes
were evaluated as alternatives to live virus in microneutralization assays using reference
sera standards, mouse and human sera collected during vaccine immunogenicity studies,
surveillance sera from seals, and monoclonal antibodies (mAbs) against IBV. The influenza
B pseudotype pMN was found to effectively detect neutralizing and cross-reactiveorg May 2021 | Volume 12 | Article 6613791
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influenza research.Keywords: influenza B, lentiviral (LV) vector, pseudotype viral particles, pseudotype neutralization, serosurveillanceINTRODUCTION
Seasonal influenza causes severe illness and mortality in high-
risk human populations such as children, the elderly, and
individuals with underlying morbidity. Influenza viruses belong
to the Orthomyxoviridae family and are enveloped negative sense
single−stranded segmented RNA viruses. Within this family,
there are three influenza types that circulate in humans:
influenza A, B, and C (1, 2). Influenza type D was recently
proposed but it appears to be confined to animal populations (3).
Influenza B virus (IBV) causes approximately 25% of all seasonal
influenza infections (4) and has also been shown to infect seals
(5) and pigs (6). IBV co-circulates with influenza A viruses (IAV)
in humans as two distinct lineages, defined as the B/Yamagata/
16/88-like viruses and B/Victoria/2/87-like lineages (7, 8). The
two B lineages have been shown to cause a comparable
proportion of influenza B cases globally, with B/Yamagata
more frequent in temperate countries, and B/Victoria in the
tropics (9). The two lineages are defined by genetic and antigenic
differences of their major surface glycoprotein hemagglutinin
(HA). Hemagglutinin (HA) is a homotrimeric type I
glycoprotein that is responsible for viral cell attachment and
entry into host cells via protein-linked sialic acid receptors (10,
11). Sialic acids are a family of carboxylated sugars that constitute
the terminal monosaccharides of animal protein glucidic
residues (12). If infection was not limited by other factors
controlling viral replication, the HA would allow broad viral
tropism, since sialic acids are present on almost all cell types
regardless of species. These limiting factors are mainly
represented by restriction of the influenza polymerase complex
activity and activation of influenza HA (10, 13–16). HA is
synthesized as a single polypeptide precursor, HA0 (78kDa)
that is then cleaved into two subunits HA1 (50−58 kDa) and
HA2 (28−22 kDa). HA cleavage, mediated by specific proteases
(17), is necessary to expose a fusion peptide in the stalk region,
and to permit HA conformational change after viral particle
endocytosis. Subsequently, this permits envelope-endosome
membrane fusion and the release of the viral core into the cell
cytosol (14). However, these factors do not completely limit the
ability of influenza viruses to infect different animal species and
as is the case with IAV, IBVs cause human infections and have
zoonotic and pandemic potential due to their ability to infect
non-human mammalian species. Interestingly, these non-human
IBVs are antigenically related to human viruses (5) indicating
that humans are the natural reservoir of IBV and that they have
limited zoonotic potential. In fact, IBV has a lower infection and
mortality rate than influenza A and this has resulted in influenza
B being relatively understudied (15).
The clinical and public health community has until recently,
underestimated the influenza B burden. It is now necessary toorg 2raise awareness of influenza B virus infection, by increasing
epidemiological surveillance and seasonal vaccination coverage
(18). Influenza B strains are included in seasonal vaccines, but
there have been instances wherein mismatches between vaccine
and circulating strains have left the at-risk population
unprotected (19). This may partially be due to IBV branching
into two distinct lineages in the 1980’s following a large−scale
genomic reassortment event involving all eight influenza B
segments (8). These two lineages continue to diverge, and are
subject to reassortment and co−circulation, although one tends
to dominate over the other for a determinate period of time (7).
To resolve the vaccine mismatch issue, quadrivalent vaccines
containing one representative strain for each influenza B lineage
together with the influenza A H1N1 and H3N2 viruses were
developed and are currently licensed (20–22). Despite improved
vaccine coverage, epidemiological surveillance and rigorous
vaccine testing are still needed (20, 23).
Classical serological assays, such as the hemagglutination
inhibition (HI), Single Radial Hemolysis (SRH), and
microneutralization (MN) assays are usually employed for
influenza surveillance (24). However, several studies have indicated
that the HI assay does not quantify Influenza B seroconversion
accurately since it underestimates antibody titers (25–27). Although,
ether−treatment of the virus during HI was shown to increase
sensitivity (28–30), this increase may be insufficient to attain SRH
and MN consistency (28, 29, 31). Additionally, classical serological
methods do not efficiently detect HA stalk−directed antibodies (32–
36), as they are known to be unable to inhibit hemagglutination, and
their discovery was hampered by this bottleneck in previous years.
HA stalk epitopes are promising targets for influenza ‘universal’
vaccines (37–39). Encouragingly, there is evidence that stalk –
directed antibodies are able to neutralize the two influenza B
lineages and in some cases, also influenza A viruses (33, 40). This
work has increased interest in studying the cross−neutralizing
response from an influenza B perspective. Monoclonal antibodies
can be employed to delineate these responses, whereupon lineage
specific or broader epitopes canbe identified and tested, yieldingdata
which would not be possible using polyclonal sera.
In recent years, the use of lentiviral vectors based on the HIV-
1 genome pseudotyped with the HAs of influenza A viruses have
been shown to be effective for studying antibody responses (32,
41, 42). An advantage of working with these influenza
pseudotypes (PV) is the possibility to investigate immune
response to influenza without the use of high containment
facilities. The use of pseudotypes enables BSL-2 research
employing viruses that are not commonly in circulation and
have high pandemic potential, as these live viruses are often
studied at BSL-3 or higher. Additionally, in vaccine studies,
high volumes of serum are required for live virus testing and
hemagglutination assays, whereas a very low sample input isMay 2021 | Volume 12 | Article 661379
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also provide a system to explore the role of HA-head or HA-
stalk-directed immune responses. It has been proposed that the
lower density of HA expressed on the vector surface permits
increased access to HA-stalk epitopes; the proposed major
mediator of the heterosubtypic antibody response (32, 43–45).
To address the aforementioned serological assay issues and
allow further study of IBV antibody responses, we have
developed a panel of lentiviral vectors pseudotyped with IBV
HAs. Herein, we describe the optimized production and
characterization of this newly established Influenza B PV
panel. Additionally, we have investigated the feasibility of using
these PV as surrogate antigens in neutralization assays, and to
study cross−neutralizing antibody responses.MATERIALS AND METHODS
Propagation and Maintenance of
Cell Lines
Human Embryonic Kidney (HEK) 293T/17 cells were used for
PV production, titration and as target cells. They were
maintained in Dulbecco’s Modified Eagle Medium (DMEM)
(PAN−Biotech P04-04510) supplemented with 15% (v/v) Fetal
Bovine Serum (FBS) (PAN−Biotech P30-8500) and 1% (v/v)
penicillin−streptomycin (Pen-Strep) (Sigma P4333).
Madin−Darby Canine Kidney (MDCK) and A549 cells were
also used as target cells to study IBV PV transduction and
tropism. Cells were cultured in DMEM supplemented with 5%
FBS and 1% of Pen-Strep and in DMEM/F-12 media (Gibco
21041033) with 10% FBS and 1% Pen-Strep, respectively.
HA, Protease, and Lentiviral Vector
Packaging Plasmid Production
B/Bangladesh/3333/2007 and B/Brisbane/60/2008 HA genes
were amplified from cDNA and subcloned into plasmidFrontiers in Immunology | www.frontiersin.org 3expression vector pI.18 (46, 47). B/Hong Kong/8/1973, B/
Victoria/2/1987, B/Yamagata/16/1988 and B/Florida/4/2006
codon optimized HA genes (Figure 1) were synthesized by
GenScript and cloned into phCMV1 as previously described
(32). B/Colorado/06/2017, B/Phuket/3073/2013, B/Brisbane/
60/2008 and B/Washington/2/2019 plasmids were synthesized
by GeneArt and cloned into pEVAC. HAT (human airway
trypsin-like protease) and TMPRSS2 (type II transmembrane
protease serine 2) (49) were cloned in pCAGGS; while
TMPRSS4 (type II transmembrane protease serine 4) (50)
was cloned in pCMV, and were used to activate influenza B
HA during lentiviral vector production. The second-generation
packaging construct pCMVDR8.91 (51), and the self-
inactivating lentiviral vectors pCSFLW expressing firefly
luciferase and pCSemGW expressing emerald green
fluorescence protein (emGFP) were used as reporters for
PV production.
Production of IBV Pseudotypes
For IBV HA in pI.18, pseudotypes were produced in 6-well plates
using branched polyethylenimine (PEI) (Sigma-Aldrich 408727)
co-transfection of 500 ng pCMVDR8.91, 750 ng pCSFLW or
pCSemGW, and 500 ng of HA-encoding plasmid. Additionally,
125 ng or 250 ng of protease-encoding plasmid was also included
in the DNA transfection mix to allow influenza B HA activation
and cleavage. For IBV HA in pEVAC, cells were transfected
using Opti-MEM™ (Thermo Fisher Scientific 31985062) and
FuGENE® HD Transfection Reagent (ProMega E2312) with 10
ng HA encoding plasmid, 375 ng pCSFLW, 250 ng
pCMVDR8.91, and 2.5-10 ng of HAT or T4 proteases. IBV PV
were also produced in the absence of protease-encoding plasmid
(D protease), and these served as controls. At least 8 hours post-
transfection, 1 unit of exogenous Neuraminidase (Sigma N2876)
was added. PV were collected 48 hours after transfection of
HEK293T/17, passed through a 0.45 µm membrane filter, and
stored at -80°C.FIGURE 1 | Phylogenetic tree of influenza B HA used for pseudotype production. Phylogenetic tree shows influenza B diverging into two distinct lineages,
B/Yamagata (blue) and B/Victoria (red). Accession numbers are reported with the strain name on the tree tips. Nodes are shown at the ends of branches which
represent sequences or hypothetical sequences at various points in evolutionary history. Branch lengths indicate the extent of genetic change. The tree generated
was constructed with PhyML (48) and graphically elaborated with Archaeopteryx.js (https://sites.google.com/site/cmzmasek/home/software/archaeopteryx-js).May 2021 | Volume 12 | Article 661379
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Different Cell Lines
Titration experiments of firefly luciferase-expressing or emerald
GFP PV were performed in Nunc™ F96 MicroWell™ white or
transparent polystyrene plates (Thermo Fisher Scientific),
respectively. The PV production titer was evaluated by
transduction of HEK293T/17, MDCK, and A549 cells, with
2−fold serial dilutions of PV in a total volume of 100 µL. As a
control for HA cleavage, D protease influenza B PV were also
activated by addition of 1 mg/mL (TPCK)-trypsin (Sigma
T1426) to a final concentration of 100 µg/mL per well. These
wells were incubated at 37°C, 5% CO2 for 30 minutes followed by
addition of 50 µL trypsin neutralizing solution (Lonza CC-5002)
to each well. For all samples and controls, 1.5x104 HEK293T/17
cells were added to each well of the 96-well plate. Plates were
incubated for 48 hours at 37°C, 5% CO2. Afterwards, firefly
luciferase gene expression was evaluated and quantified using the
Bright−Glo™ assay system (Promega E2620) and GloMax Multi
detection system luminometer (Promega) as shown previously
(52). Influenza B PV produced with emerald GFP were also
tested, using an equivalent protocol, for their ability to transduce
HEK293T/17, MDCK, and A549 cells.
Serum Samples and
Monoclonal Antibodies
Antisera against B/Brisbane/60/2008 (NIBSC 11/136) was
obtained from the National Institute for Biological Standards
and Control (NIBSC) and used as the primary antibody in
western blot experiments and positive control in neutralization
assays. Post-vaccination mouse sera were obtained from the
University of Cambridge as part of an ongoing influenza
vaccination study and were employed to determine responses
of different antigens used for vaccination against IBV PV.
Human sera obtained during the clinical trial NCT00942071
(53) were used in PV neutralization assays (pMN). These sera
were collected from adults aged 50 years and over pre− and post−
administration of an influenza split virion vaccine (Sanofi
Pasteur MSD, France) that contained HAs of A/California/7/
2009 (H1N1), A/Perth/16/2009 (H3N2), and B/Brisbane/60/
2008. Nine subjects received an injection of Modified Vaccinia
Ankara (MVA) vectors expressing the A/Panama/2007/
1999 (H3N2) nucleoprotein (NP) and matrix protein 1 (M1)
(MVA−NP+M1) antigens as a single fusion protein (53, 54). The
remaining subjects (n=8) received a trivalent inactivated vaccine
(TIV) and saline placebo. These sera were previously analyzed
(53) in an HI assay against B/Brisbane/60/2008. Seal serum
samples (n=8) were obtained from the University of Veterinary
Medicine, Vienna, Austria, as part of a wildlife and conservation
study of seals caught in the Caspian Sea (CS) from 2006-2010 at
the Europe/Asia border. We obtained previously characterized
neutralizing monoclonal antibodies (55) from the Division of
Viral Products, Food and Drug Administration, USA.
Monoclonal antibodies designated 5A1 specific to the B/
Victoria lineage, 3E8, specific to the B/Yamagata lineage, and
2F11 specific to both B/Victoria and B/Yamagata lineages are
used herein to evaluate PV neutralization activity (55).Frontiers in Immunology | www.frontiersin.org 4Western Blotting
Briefly, 2 ml of PV was centrifuged at 3000xg at 4°C for 24 hours.
Supernatant was removed and resuspended in 150 µL
OptiMEM™. SDS−PAGE of reduced and denatured influenza
B PV was carried out in 4−15% Mini−PROTEAN® TGX™
precast polyacrylamide gels (Bio−Rad 4561024) following
manufacturer’s instructions. The gel was transferred onto an
Immuno−Blot® low fluorescence polyvinylidene fluoride
membrane (PVDF) (Bio−Rad 1620260) for 60 minutes at
100 V. The membrane was blocked overnight with blocking
buffer (10% (w/v) dried milk, 0.01% (v/v) Tween20−PBS). The
anti−B/Brisbane/60/2008 serum (NIBSC 11/136) was used as
the primary antibody, diluted 1:500 in blocking buffer. The
membrane was washed with 0.01% (v/v) Tween20−PBS prior
to addition of secondary antibody, IgG Dylight®800 antibody
diluted 1:20000 in blocking buffer. After washing to remove
unbound secondary antibody, the PVDF membrane was
visualized using the Odyssey® Sa Infrared Imaging System
(LI−COR Bioscience) at 800 nm.
Pseudotype Microneutralization
Assay (pMN)
The neutralization activity of anti−B/Brisbane/60/2008 serum
(NIBSC 11/136) (starting dilution 1:1000), post-vaccination
mouse sera (University of Cambridge), sera from the
NCT00942071 (53) human clinical trial, and mAbs from Food
and Drug Administration (USA) were evaluated against different
influenza B pseudotypes produced in this study by performing
the pMN according to established protocol (52). Briefly, 2−fold
serial dilutions of serum or mAbs were performed in a Nunc™
F96 MicroWell™ white polystyrene plate. The plate was
centrifuged for 1 min at 500xg and 50 µL of influenza B PV
solution with a concentration 1×106 relative luminescence units
(RLU) was added to each well. The plate was again centrifuged
for 1 min at 500xg and incubated at 37°C, 5% CO2. Afterwards 50
µL of 1.5×104 HEK293T/17 cells were added to each well and
after a final centrifugation for 1 minute at 500xg, the plate was
incubated at 37°C, 5% CO2 for 48 hours. Firefly luciferase gene
expression was evaluated as previously described. Additionally,
the neutralization activity of a panel of seal sera was also
evaluated using a starting dilution of 1:100 (Supplementary
Table 1). Human positive controls were obtained from Prof.
Emanuele Montomoli at the University of Siena (starting
dilution 1:1000). The negative control used was FBS (starting
dilution 1:100).
Statistical Analysis
All analyses were performed with GraphPad Prism 8.12 for
Windows (GraphPad Software). A non−parametric Analysis of
variance (ANOVA) was carried out to determine whether
differences exist among the means of three or more groups
when compared to control. If differences were found, the post-
hoc Tukey multiple comparison test was performed to identify if
there is a significant difference between pairs of experimental
groups. Wilcoxon matched−pairs signed rank test was used to
assess statistical significance between day 0 and day 21 in theMay 2021 | Volume 12 | Article 661379
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Clinical trial data were also then stratified based on vaccine
regimen: TIV + placebo or TIV + MVA−NP+M1, to evaluate the
effect of MVA−NP+M1 in broadening the heterosubtypic
antibody response. To avoid multiple comparisons, statistical
analysis was performed using the IC50 fold−increase between
TIV + placebo and the TIV + MVA−NP+M1 groups in a
Mann−Whitney U test.
Bioinformatic Analysis
Influenza B HA gene sequences that were used in PV production
were used to calculate percentage identity between amino acid
sequences, and for phylogenetic analysis. First, HA−encoding
sequences were downloaded from the Influenza Virus Resource
database (IVRD). Then, percentage identity between amino acid
sequences was calculated by pair−wise alignment using
Jalview (56).
For phylogenetic analysis, codon−based alignment was
performed using the MUSCLE algorithm (57) in Molecular
Evolutionary Genet ics Analysis (MEGA) (58). The
phylogenetic “Quick Tree” model used PhyML (48) and pre-
defined settings by the Influenza Resource Database of the
National Institute of Allergy and Infectious Diseases (NIH/
DHHS) to infer phylogenies based on sequences (https://www.
fludb.org/brc/tree.spg). The tree generated was then graphically
elaborated with Archaeopteryx.js (https://sites.google.com/site/
cmzmasek/home/software/archaeopteryx-js) in phyloXML
and format.RESULTS
Co-Transfection With a Protease-
Encoding Plasmid Produces High Titer
Influenza B PV
Proteases were previously reported to be necessary for
production of high titer influenza A pseudotypes (50, 59). Here
we have employed three different proteases that are associated
with influenza A HA cleavage: HAT, TMPRSS2, and TMPRSS4,
to show how they will affect IBV PV production. We have used
fixed amounts of HA-encoding plasmid, packaging construct,
and lentiviral reporter plasmids, only varying the type and
amount of protease-encoding plasmid in the transfection. For
IBV HA in pI.18, the highest titers of around 109 RLU/mL were
achieved using HAT as protease, except for B/Brisbane/60/08
which achieved its highest titer of ~108 RLU/mL with TMPRSS4
(Figure 2A). For all PV, co-transfection with TMPRSS2 achieved
the lowest titers, ~105-108 RLU/mL, a log down from titers
produced via HAT (Figure 2A). In the absence of protease
(Dprotease), influenza PV are still produced, but titers only
reached ~105 RLU/mL at best, at least 3 logs lower than PV
produced in the presence of protease. These PV (Dprotease) were
added with TPCK-Trypsin post-production and prior to titration
to activate HA cleavage. PV titers increased at least 3-logs
compared to Dprotease titers (Figure 2A). We co-transfected
with HAT and TMPRSS4 proteases to produce PV from IBV HAFrontiers in Immunology | www.frontiersin.org 5in pEVAC. For transfections with the IBV HA pEVAC plasmids,
we used significantly less plasmid DNA, 10 ng of the IBV HA
plasmid, 250 ng of the packaging plasmid, 375 ng of the
luciferase reporter plasmid, and 2.5-10 ng of protease-encoding
plasmid. We obtained titers of ~1010 RLU/mL for all PV
produced via co-transfection with HAT, and 109-1010 RLU/mL
with TMPRSS4 co-transfection (Figure 2B). The difference in
titers observed for B/Brisbane/60/2008 produced may be
attributed to the employment of a different plasmid backbone
(pI.18 vs pEVAC), and the transfection agents used. Results
indicate that transduction titers of different influenza B PV are
dependent on the type of protease used and on the quantity of
protease-encoding plasmid employed in transfection, with
amounts being adjusted to produce optimal titers.
Proteases Activate Influenza B PV
via HA Cleavage
The HA of both IAV and IBV are synthesized as an inactive
precursor HA0, and its proteolytic cleavage into the mature
HA1/HA2 form is a prerequisite for the low pH-induced,
irreversible HA conformational change that is essential for
virus infectivity (10, 14, 49, 60, 61). To confirm that the
addition of an extracellular protease during transfection
mediates HA cleavage, a western blot was performed on the B/
Brisbane/60/2008 (from pI.18) PV produced. In all B/Brisbane/
60/2008 PV produced with the addition of HAT, TMPRSS2 and
TMPRSS4, bands corresponding to HA1 (~55kDa) can be
observed (Supplementary Figure 1). Darker and heavier HA1
bands are observed for PV produced with HAT and TMPRSS4
compared to TMPRSS2. These band intensities correlate with PV
titers (Figure 2A). Interestingly, PV HA activated by HAT,
TMPRSS2 and TMPRSS4 present heterogeneous glycosylation
characteristics: more than one band between 50 kDa and 60 kDa,
all corresponding to HA1, are present, whereas in the Dprotease
PV before and after TPCK−trypsin treatment, only a single band
at ~55 kDa is observed (Supplementary Figure 1). This band
at ~55 kDa shows limited HA0 cleavage and probable HA
activation even without proteases (Supplementary Figure 1).
It is also observed that the HA cleavage mediated by proteases
can be reproduced through TPCK−trypsin treatment of the
D protease PV, as the HA0 band was replaced by bands
corresponding to the HA cleavage products (Supplementary
Figure 1).
Influenza B PV Can Transduce
Different Cell Lines
We tested whether IBV pseudotypes can transduce HEK293T/
17, MDCK, and A549 cells at high titer. Employing transfection
with pCSFLW (firefly luciferase) (Figure 3A) and emGFP
(Figure 3B), it was found that all IBV pseudotypes are able to
transduce all cell lines. It was shown that the IBV PV transduces
HEK293T/17 cells more effectively than the classical influenza
producing cell lines, MDCK and A549. Titers in HEK293T/17
cells are in the range of 5x107-1010 RLU/mL (Figure 3A) whilst
titers were in the range of 104-108 RLU/mL for pseudotypes
using both MDCK and A549 as target cells (Figure 3A).May 2021 | Volume 12 | Article 661379
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titration and neutralization assays involving IBV PV in
this study.
Influenza B Pseudotypes as Tools to
Assess Vaccine Immunogenicity and for
Serological Surveillance
We have investigated the utility of influenza B pseudotypes as
substitutes for live viruses in influenza neutralization
serological studies. We employed standard reference antisera,
mouse sera from vaccination studies, human sera from an
influenza clinical trial, and sera from seals, a known natural
host of influenza B, to test the IBV PV we produced in thisFrontiers in Immunology | www.frontiersin.org 6study. First, we tested if three of the six IBV PV from pI.18 we
have generated (Figure 2A) and one IBV PV from pEVAC
(Figure 2B) could be neutralized by anti-B/Brisbane/60/2008
HA serum (NIBSC 11/36). We chose to test B/Brisbane/60/
2008 from the B/Victoria lineage, B/Florida/4/2006 from the B/
Yamagata lineage, representing strains of co-circulating
influenza B lineages previously or currently used in influenza
seasonal vaccination, and B/Hong Kong/8/1973, as a
representative strain circulating before the influenza B lineage
division (Figure 1). It was found that the reference serum
employed completely neutralized all the IBV PV tested up to
the dilution 1:1600 (Figure 4A). The anti-serum neutralized the
homologous B/Brisbane/60/2008 most efficiently, followed byA
B
FIGURE 2 | Production of influenza B pseudotypes employing different proteases. Various quantities of proteases were co-transfected with gag-pol packaging
construct, firefly luciferase and influenza B HA-encoding plasmids in pI.18 (A) or pEVAC (B). (A) For transfection employing pI.18 HA plasmids, HAT, TMPRSS2 and
TMPRSS4 were used in 250 and 125 ng quantities. Pseudotypes produced in the absence of protease (Dprotease) and those activated post-transfection and pre-
titration with TPCK-Trypsin are also included. Plates were read using the Bright-Glo™ assay system (Promega) and GloMax Multi detection system luminometer
(Promega). (B) For transfection employing pEVAC plasmids, only HAT and TMPRSS4 proteases in the range of 2.5 ng-10 ng were used. Titration plates were then
read using the GloMax® Navigator (ProMega) using the Promega GloMax® Luminescence Quick-Read protocol. For both (A, B), pseudotype virus titers are
expressed in relative luminescence units/mL (RLU/mL). Significant differences between titers obtained for each PV grouped into protease used and Dprotease are
shown via brackets (*p=<0.05). Error bars show mean and standard deviation of four replicates.May 2021 | Volume 12 | Article 661379
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with B/Brisbane/60/2008, and B/Florida/4/2006 (93.5% amino
acid identity) (Figures 1, 4A). There was no difference in
neutralization of B/Brisbane/60/2008 PV produced from
either pI.18 or pEVAC when used in the same input RLU by
anti-B/Brisbane/60/2008 HA serum (NIBSC 11/36) (Figure
4A). As such, the PV neutralization assay (pMN) with
reference antisera was able to differentiate between the
different PV, showing correlation between amino acid
identity and neutralization efficacy.
Pre-clinical utility: We have obtained sera from Influenza B
vaccination studies in mice at the University of Cambridge, and
we have tested the ability of these mouse sera to neutralize the
IBV pseudotypes, B/Phuket/3073/2013 from the B/Yamagata
lineage and B/Washington/2/2019 from the B/Victoria lineage,
that we produced using pEVAC-HA (Figure 2B). Naïve mice
were vaccinated with the HA of B/Singapore/222/1972 (pre-split
IBV), B/Colorado/06/2017 (B/Victoria lineage), B/Phuket/3073/
2013 (B/Yamagata lineage), and PBS (negative control) to elicitFrontiers in Immunology | www.frontiersin.org 7an immune response against influenza B. Mouse terminal bleeds
were taken, and sera were run on pMN assays to obtain IC50 data
and assess vaccine immunogenicity. Post-vaccination sera from
groups given B/Colorado/06/2017 and B/Phuket/3073/2013 were
able to neutralize both IBV pseudotypes tested regardless of
lineage (Figure 4B) compared to the PBS control (*p<0.05).
Vaccination with B/Colorado/06/2017 (B/Victoria) showed
highest neutralization against the B/Victoria lineage PV, B/
Washington/2/2019. Similarly, vaccination with B/Phuket/
3073/2013 (B/Yamagata) neutralized the B/Phuket/3073/2013
PV better than the B/Victoria lineage PV (Figure 4B). Mice
vaccinated with pre-split B/Singapore/222/1972 was unable to
neutralize both IBV with IC50 dilutions showing no significant
difference (p>0.05) to the mice vaccinated with PBS (Figure 4B).
IC50 dilutions were in the range of 10
2 – 105 for mice vaccinated
with either B/Colorado/06/2017 or B/Phuket/3073/2013 against
both IBV PV (Figure 4B). indicating development of an immune
response post-vaccination that can be effectively assessed via the
PV neutralization assay.A
B
FIGURE 3 | Influenza B pseudotypes are expressed in different cell lines. (A) Titers of influenza B pseudotypes expressing firefly luciferase in HEK293T/17, MDCK,
and A549 cells are shown in RLU/mL as the mean and standard deviation of 4 replicates. A DHA control representing non-HA pseudotyped virus was included for
comparisons. No significant difference between PV titers and DHA is indicated by brackets (n.s. p>0.05). (B) Influenza B lentiviral pseudotype B/Florida/4/2006
containing an emerald GFP reporter is shown to successfully transduce HEK293T/17, MDCK and A549 cells. Scale bar = 6 µm.May 2021 | Volume 12 | Article 661379
Ferrara et al. Influenza B PseudotypesClinical utility: To further investigate the suitability of
influenza B pMN assays in vaccine immunogenicity studies
and to detect cross−reactive responses to influenza B, we
employed human sera from clinical trial NCT00942071 (53).
The panel of human sera was provided by Professor Sarah
Gilbert (University of Oxford). Using the IBV PV we produced
in pI.18, we determined the levels of anti-IBV neutralizing
antibodies pre- and post-vaccination with a Trivalent Influenza
Vaccine (TIV) (Figure 5A). All participants (n=17) had
pre-existing antibody response to Flu B – mean IC50 dilution
of ~61341. These responses were significantly boosted against
2/3 IBV PV tested; B/Hong Kong/8/1973 a pre-split PV (Figure
5A (ii) (p=0.0046Wilcoxon paired U test) and B/Florida/4/2006,
of Yamagata lineage (Figure 5A (iii) (p=0.0129 Wilcoxon paired
U test). However, none of the participants had boosted responses
against B/Brisbane/60/2008 of Victoria lineage (p=0.5791
Wilcoxon paired U test). Trial participants received an
additional vaccination with either a placebo (saline solution)
(n=8) or an MVA-NP-M1 fusion protein (n=9) (53). Antrobus
et al. (53) have demonstrated that this additional boost with NP-
M1 fusion MVA increased T cell responses to internal influenza
proteins. They suggest that this may have helped HA-specific B
cells leading to the increased seroprotection and seroconversion
to H3N2 they reported (53). Therefore, post vaccination samples
were compared between those who had received the NP-M1
fusion MVA and those who received the placebo to determine if
this effect was responsible for the increase in post vaccination
antibodies observed herein (Figure 5A). However, once post-
vaccination IC50 values were grouped based on the vaccine
regimens administered, no significant difference was found in
the IC50 fold differences between pre-vaccination and post-Frontiers in Immunology | www.frontiersin.org 8vaccination values against any of the PV tested (Figure 5B).
The range of responses was also greater in those participants who
received TIV followed by MVA-NP-M1 fusion protein
compared to those who received TIV followed by the placebo.
Currently the gold standard for determining vaccine efficacy
is to test responses using hemagglutination inhibition (HI) and
single radial hemolysis (SRH). We believe that these assays can
be complemented by the use of pMN especially in the initial
testing of novel vaccine candidate responses. Recently, it has
been shown that influenza B pMN fold changes (IC50) correlates
strongly to SRH and HI assays (62). However, the HI assay is
only able to detect antibodies directed against the HA head and
we have not differentiated stem responses herein and so this may
account for the weak correlation with the HI data presented in
the clinical trial (r=0.1632, p=0.3563) (53) (Supplementary
Figure 2).
Serological surveillance studies monitor the virus and its
reservoirs to aid in vaccine choice and treatment. To test
whether the pseudotyped IBV could be used to test non-
human sera, we obtained seal sera from an influenza
surveillance study conducted by the University of Vienna. We
evaluated these samples for neutralizing activity against influenza
B strains, B/Hong Kong/8/1973, B/Yamagata/16/1988, and B/
Victoria/2/1987 from pI.18 (Figure 2A) using pMN. In the
limited number of sera tested, only a single positive signal was
observed, against B/Victoria (IC50 = 44) (Supplementary
Table 1), with none of the other serum samples showing
neutralizing activity against any of the IBV PV tested. This
correlates with previous data showing a prevalence of
antibodies to IBV in only 2% of seals tested (n=971) after
1995 (5).A B
FIGURE 4 | Neutralization of influenza B pseudotypes by reference antisera and mouse sera from influenza vaccination studies. (A) Neutralization of
pseudotypes from pI.18, B/Brisbane/60/2008, B/Florida/4/2006, and B/Hong Kong/8/1973 against reference antisera anti-B/Brisbane/60/2008 (NIBSC 11/36)
was measured by a luciferase reporter assay. Reference sera was serially diluted two-fold from a starting dilution of 1:100. 1.0x106 RLU of IBV PV was then
added to each well. For all plots, each point represents the mean and standard error of four replicates per dilution. (B) In vitro neutralization of influenza B
pseudotypes from pEVAC, B/Phuket/3073/2013 and B/Washington/2/2019 by mouse sera vaccinated with Influenza B HA from B/Singapore/222/1972, B/
Colorado/6/2017, B/Phuket/3073/2013, and PBS (negative control). Neutralization was determined via a luciferase-reporter assay and given as IC50 dilution
values (In this case, IC50 is half maximal inhibitory serum dilution). Significant difference between the means of the IC50 values of the groups vaccinated with IBV
HA against the PBS negative control group are shown via brackets (*p<0.05). Interleaved box plots show minimum, maximum, and mean values. Error bars
show standard deviation of replicates. For mice vaccinated with B/Singapore/222/1972 HA, n = 5 mice/group; n = 6 mice/group for mice vaccinated with B/
Colorado/6/2017 HA, B/Phuket/3073/2013 HA, and PBS.May 2021 | Volume 12 | Article 661379
Ferrara et al. Influenza B PseudotypesInfluenza B pMN to Assess Monoclonal
Antibody Specificity Against IBV PV From
Different Lineages
We tested the influenza B pseudotypes produced from pEVAC-
HA (Figure 2B) against monoclonal antibodies obtained from
the Food and Drug Administration, USA. Monoclonal antibody
3E8, specific to B/Yamagata viruses, was able to neutralize B/
Phuket/3073/2013 from the B/Yamagata lineage with an IC50 of
18.77 ng/mL (Figure 6). However, 3E8 was unable to neutralize
the B/Victoria lineage pseudotype. On the other hand, 5A1,
specific to B/Victoria viruses, was able to neutralize B/Brisbane/
60/2008 from the B/Victoria lineage with an IC50 of 206 ng/mL
(Figure 6). Monoclonal antibody 5A1 was unable to neutralize
the B/Yamagata lineage virus. Monoclonal antibody 2F11 which
was previously reported to neutralize both B lineages was unable
to neutralize both IBV PV at the concentrations tested
(Figure 6). Our results for 2F11 against B/Brisbane/60/2008Frontiers in Immunology | www.frontiersin.org 9correlate with Carnell, 2021 (62) and we have employed a
more recent B/Yamagata-like virus in this study, B/Phuket/
3073/2013, compared to those tested previously, which may
explain non-neutralization. Epitope mapping of the mAb
binding site in these IBV may be done in future to determine
if genetic change throughout the years may have influenced
neutralization of IBV by this mAb. We have also shown here that
neutralization of the IBV pseudotypes we tested was
lineage-specific.DISCUSSION
Knowledge of the life cycle of the influenza B virus is essential for
production of high titer IBV pseudotypes. HA activation through
proteolytic cleavage is an integral part of IBV replication. This
process of “activation” enables low−pH dependent fusion of theA
B
FIGURE 5 | Evaluation of IBV neutralization capacity of NCT0942071 clinical trial sera using influenza B pseudotype microneutralization assay (pMN). The
neutralization capacity of human sera from clinical trial (NCT0942071) was assessed pre- and post-vaccination with Trivalent Influenza Vaccine (TIV) and then either a
placebo saline solution or an MVA-NP fusion protein (n=17). All sera were serially diluted and incubated with each PV: (i) B/Brisbane/60/2008, (ii) B/Hong Kong/8/
1973, and (iii) B/Florida/4/2006 PV before addition of HEK293T/17 cells. Residual luciferase activity was determined and % neutralization was calculated relative to
the PV only control. From this, IC50 values were calculated as the reciprocal of the dilution required to neutralize 50% of initial input PV. Significant differences
between the means of pre- and post-vaccination sera IC50 when tested against PV are indicated in brackets (*p<0.05) (A). After data stratification on the basis of
post-TIV vaccine regimens; TIV + placebo (n=8), TIV+MVA+NP+M1 (n=9), the fold-increase from pre-vaccination IC50 titers were compared to post-vaccination IC50
(B). Data is compared using Tukey plots showing the median of the 25th and 75th percentile with outliers plotted as those which exceeded 1.5x quartile range. Virus
pseudotype from B/Victoria lineage is indicated in red and B/Yamagata lineage in blue.May 2021 | Volume 12 | Article 661379
Ferrara et al. Influenza B PseudotypesHA envelope with the endosomal membrane leading to
endocytosis of the virus, followed by release of the viral core
into the cytosol (63). For influenza B, HA activation has been
observed in embryonated chicken eggs (64), and in both a
trypsin−dependent and independent manner in MDCK cells
(65, 66). Additionally, experiments have shown that
neuraminidase could also have a role in HA activation by
removing glucidic residues on the HA surface (67, 68).
Furthermore, it was shown that influenza B HA can be cleaved
by porcine pancreatic elastase when the cleavage-linked arginine
is substituted with an alanine or a valine (61). Influenza B HA
can also partially support a poly−basic cleavage site that permits
the cleavage by subtilisin−like proteases (60).
More recently, HAT, TMPRSS2, TMPRSS4, and a range of
other transmembrane serine proteases (TSP) have been shown to
be able to cleave and activate influenza B HA in in vitro models
(15, 49, 69). Guided by these findings, we were able to produce
high titer IBV PV by including TMPRSS2, TMPRSS4 or HAT
protease plasmids in the transfection mix (Figure 2A). In the
absence of protease (Dprotease), IBV PV are still produced
(Figure 2A). However, only a small proportion of HA is
cleaved by endogenous proteases in the producer HEK293T/17
cells (17). This is illustrated by the presence of the HA1 band,
evidence of a cleaved HA0 in Dprotease-produced viruses
(Supplementary Figure 1). This also further explains the entry
of D protease PV into HEK293T/17 target cell lines observed
during titration experiments. We also utilized exogenous
bacterial neuraminidase (NA) for PV production. It has been
shown that this NA can play a role in removing glucidic residues
from the HA surface, to enhance viral attachment to the receptor
(60). However, the addition of exogenous NA to D protease PV
did not result in heterogeneous glycosylation of HA
(Supplementary Figure 1). Our data suggest that it is likely
that the proteases we employed (especially TMPRSS2) mediate
HA cleavage intracellularly (70), via interaction with cell
glycosylation machinery (71). These findings confirm the
importance of host proteases for IBV replication in
concurrence with other in vitro studies (15, 17, 49, 69).Frontiers in Immunology | www.frontiersin.org 10Here we have shown successful transduction of Influenza B
pseudotypes in 3 different cell lines with varying titers (Figure 3).
It has previously been found that lentiviral particles are produced
at high titer in HEK293T cell lines which contain the SV40 T-
antigen (72, 73). HEK293T cells have been shown to have shorter
doubling times and higher transfection efficiency leading to
higher vector titer (74) compared to other cell lines. Several
factors influence IBV HA transduction efficacy into target cells.
Firstly, different strains of IBVHA bind preferentially to different
sialoglycan residues present on the glycoprotein surface of target
cells to mediate cell entry (16, 75). Secondly, “hot” cells/cell lines
can present different proportions of sialic acid combinations (65,
76). This could be important for transduction into certain cell
lines, in relation to differential sialic acid distribution between
cells (77). The lipid bilayer and the characteristics of the
membrane lipids can also play an important role in
transduction as lipid composition has been implicated in
membrane fusion (13, 78). Pizzato et al. and Voelkel et al. have
observed that lentiviral vector particles are able to bind to the cell
membrane and are endocytosed even in absence of envelope
proteins (79, 80) and may explain the increased titer in
HEK293T/17 cells over MDCK cells (Figure 3A). Given these
findings, we utilized HEK293T/17 cells as our target cells
going forward.
The influenza microneutralization (MN) assay is highly
sensitive and specific for detecting virus-specific neutralizing
antibodies against influenza viruses (24). However, it is not
logistically easy to deal with live influenza viruses that are not
widespread in the population, requiring special facilities and
training. The use of pseudotyped viruses presents a good
alternative to live viruses for research. It was previously
reported that neutralizing antibody titers against H5N1
determined by the pseudotype assay (pMN), strongly
correlated with titers obtained via traditional HI assays using
horse erythrocytes and MN assays for human, ferret and avian
sera (47). It was also found to be significantly more sensitive for
the detection of antibodies to H5 HA than the established
method which uses turkey erythrocytes in HI assays (24, 47).FIGURE 6 | Neutralization of influenza B strains by lineage-specific monoclonal antibodies. Neutralization of influenza B pseudotypes B/Phuket/3073/2013 and B/
Brisbane/60/2008 by monoclonal antibodies 3E8, 2F11, and 5A1, was measured by a luciferase reporter assay. Monoclonal antibodies were serially diluted two-fold
from a starting concentration ranging from 2000 ng/mL to 0.0625 ng/mL against all pseudotypes tested. Influenza B pseudotypes (1.0x106 RLU) were then added to
each well. For all plots, each point represents the mean and standard error of two replicates per dilution.May 2021 | Volume 12 | Article 661379
Ferrara et al. Influenza B PseudotypesIn this study, we have utilized the pMN to assess PV sensitivity to
reference antisera utilized in vaccine production, vaccine
immunogenicity in both mice and human studies, and as a
tool in sero-surveillance studies.
The characterization of influenza viruses involves subtype
generation and assessment of pathogenicity and is an important
step in developing an appropriate regulatory response against the
disease. The hemagglutination inhibition (HI) test using
reference antisera is the standard method used to subtype
influenza (24). Here, we tested the pseudotypes we produced
against reference antisera generated by NIBSC that are routinely
used to develop vaccine strains. Our results show that the pMN
was able to assess the antigenic similarity and/or differences
among the influenza B pseudotypes we tested (Figure 4A).
Antibodies in the anti-B/Brisbane/60/2008 sera were able to
neutralize the homologous virus as well as an IBV from the
other B lineage and pre-split IBV with differing efficacy
(Figure 4A). These results are promising, as we can compare
antigenic changes in currently circulating influenza viruses with
influenza viruses that have circulated in the past to aid in optimal
vaccine selection.
Vaccine studies are carried out to demonstrate the ability of
various antigens to elicit protective immune responses in different
hosts, usually in mice, ferrets, humans, and domestic poultry, as in
the case of influenza. Pre-clinical testing of potential vaccine
candidates includes in vitro assays to check for efficacy and in
vivo assays using appropriate animal models. We have used our
developed pMN assay with IBV PV we produced to test mouse
sera vaccinated with various influenza B HA intended to produce
an immune response again influenza B. Our study shows that
vaccination in mice of B/Colorado/06/2017 and B/Phuket/3073/
2013 antigens produced a measurable neutralization response
against the IBV pseudotypes tested from both B/Victoria and B/
Yamagata lineages that is significantly different from mice
vaccinated with PBS (negative control) (Figure 4B). IC50
dilution values for each antigen against a particular IBV PV can
easily be determined from serum titration curves. This makes the
pMN using IBV pseudotypes an invaluable tool in testing vaccine
immunogenicity and efficacy going forward.
We also evaluated vaccine efficacy using human serum
samples from the NCT00942071 clinical trial against B/
Hong Kong/8/1973, a PV that has antigenic characteristics
typical of influenza B strains circulating pre-lineage split, and
B/Florida/4/2006 from the B/Yamagata lineage (Figure 5A). The
pMN was able to detect neutralizing responses against both PV
at all time points tested. Pre-vaccination responses were
expected, as the age of the participants in this clinical trial (50
years and above) (53), made these subjects likely to have already
encountered the two strains (B/Florida/4/2006 and B/
Hong Kong/8/1973) pre-vaccination. Therefore, a certain level
of antibodies against these two strains could already be present.
However, the high titers observed, especially against the B/
Hong Kong/8/1973 PV, and the increase in the neutralization
titer after vaccination, indicate a certain level of cross−reactivity.
It was previously shown that seroconversion and
concomitant increase in antibody response was observedFrontiers in Immunology | www.frontiersin.org 11against a B/Yamagata strain when a trivalent vaccine
containing a B/Victoria lineage strain was administered after
priming with a Yamagata-strain containing vaccine (81).
Similar responses were found herein when neutralization in
sera from clinical trial NCT00942071 (53) was assessed via the
pMN assay. In this trial, a Victoria lineage-based vaccine (B/
Brisbane/60/2008) was administered. However, a significant
increase in the neutralizing antibody response was only found
against a B/Yamagata strain (B/Florida/4/2006) and a pre
−lineage split strain (B/Hong Kong/8/1973) and not the B/
Victoria lineage vaccine strain. This could indicate that the
cross-reactivity between influenza B viruses is primarily related
to “antigenic-sin” (82) or that influenza B responses could be
driven by antibodies able to cross-react between different
influenza B strains.
We further analyzed whether our pMN data had any
correlation with the HI data presented in the clinical trial (53).
We found weak correlation (r = 0.1632, p = 0.3563) between the
two data sets (Supplementary Figure 2). This is not surprising
since the influenza B HI assay has previously been demonstrated
to have high variability and low sensitivity (25, 27). It is also
known that the HI was unable to detect antigenic differences
between influenza B viruses until the 1980’s (8), even with
phylogenetic analyses showing that the two distinct lineages
were already present in the second half of the 1970’s (7). The
differences observed could also be due to the fact that these assays
measure different antibody responses (83), with the HI only able
to detect responses against the HA head, while the pMN is able to
detect both anti-head and anti-stalk neutralizing antibodies (32,
42, 43, 84). It will be necessary to test other sets of sera to better
understand correlation between Influenza B pMN and the classic
HI assay.
We have also used the pMN assay for influenza surveillance in
populations other than humans that may be affected by a
zoonotic disease such as influenza. Compared to influenza A,
influenza B has only been detected in a limited number of
species. Although humans are considered the natural reservoir
for IBV, seals have been found to have strains of IBV circulating
in approximately 2% of the population (5). The seal sera assessed
with the pMN assay here only detected a neutralizing response
from one sample which may be due to the low prevalence of IBV
in the seal population at the time of sample collection. Therefore,
more samples would have to be assessed in strategic locations
and timepoints in order to evaluate the potential of the pMN as a
screening tool for wildlife surveillance purposes.
Our results demonstrate the ease in which we detected
neutralizing activity of lineage-specific monoclonal antibodies
against our influenza B pseudotypes. Neutralizing responses of
monoclonal antibodies could discriminate between IBV of
different lineages. At present, monoclonal antibodies able to
cross-neutralize the two influenza B lineages have been isolated
from humans and it was shown that they recognize epitopes
present at the hinge of the HA head and stalk region or in the stalk
region itself (33). However, serological studies have failed to
identify these influenza B antibodies mainly as a result of the
insensitivity of the classical experimental tools for HA stalkMay 2021 | Volume 12 | Article 661379
Ferrara et al. Influenza B Pseudotypesantibody detection. pMN assays can detect responses from both
HA-head and HA-stalk directed antibodies. From this standpoint,
we have recently shown that the pMN assay strongly correlates
with hemagglutination Inhibition and Single Radial Hemolysis
when strains from the Yamagata lineage are tested [62]. Further
studies should be performed to understand how Influenza B pMN
assay correlates with classic microneutralization assays. These
studies could also be enhanced by using an influenza B version
of an influenza A chimeric PV assay that can delineate functional
antibody responses directed against the head from those directed
against the stalk (85). The pMN we developed could be further
utilized for these purposes.
The data presented in this paper demonstrate the successful
production of high titer influenza B pseudotypes using a
quadruple plasmid transfection method consisting of HA-
containing plasmid, HIV-1 gag-pol packaging construct,
luciferase or GFP transfer cassette, and protease, similar to
influenza A pseudotype production. The influenza B
pseudotypes we have produced here have been shown to
measure immune responses against HA with strain and lineage
specificity as well as cross-reactivity from various subjects and
samples. The influenza B pseudotype neutralization assay can be
used to assess potential vaccine candidates, monitor response to
vaccination and other interventions, and for surveillance of
zoonotic and emerging infections. As such, the next steps will
involve further assessing the correlation between pMN and the
classic microneutralization and hemagglutination inhibition
assays using live virus to establish influenza B sero-protective
titers that involve both head and stalk antibodies. These IBV
pseudotypes may be indispensable tools that can help minimize
the impact of the disease through the use of safe and effective
neutralization assays that may guide better influenza control and
intervention measures.DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.ETHICS STATEMENT
The trial protocol was approved within the UK by the Medicines
and Healthcare products Regulatory Agency and the GeneFrontiers in Immunology | www.frontiersin.org 12Therapy Advisory Committee. The trial was registered at
www.clinicaltrials.gov (identifier: NCT00942071).AUTHOR CONTRIBUTIONS
Conceived and designed experiments – FF, JD, KC, GC, SS, and
NT. Performed experiments – FF, JD, KC, RK, and GC. Analyzed
the data – FF, JD, KC, RK, GC, and NT. Reagent provision – SS,
CT, PK, and SG. Wrote the paper – FF, JD, KC, NT. Revised the
paper – GC and SS. FF and JD contributed equally to this study.
All authors contributed to the article and approved the
submitted version.FUNDING
NT, GC, KC, and RK receive funding from the Bill and Melinda
Gates Foundation: Grand Challenges Universal Influenza
vaccines Award: Ref: G101404. NT and JMD receive funding
from Innovate UK, UK Research and Innovation (UKRI) for the
project: Digital Immune Optimized and Selected Pan-Influenza
Vaccine Antigens (DIOS-PIVa) Award Ref: 105078.ACKNOWLEDGMENTS
We would like to thank Dr. Davide Corti (Humabs BioMed SA,
6500 Bellinzona, Switzerland) for providing the HA phCMV1
plasmids, Prof. Greg Towers (University College London, UK)
for the pCSemGW plasmid, and Prof. Stefan Pöhlmann
(Infection Biology Unit, German Primate Center, Göttingen,
Germany) for the HAT and TMPRSS2 plasmids. We would
also like to acknowledge Jerry Weir of the U.S. Food and Drug
Administration (10903 New Hampshire Avenue, Silver Spring,
MD 20993, USA) for the influenza B monoclonal antibodies we
used in this study.SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.
661379/full#supplementary-materialREFERENCES
1. World Health Organization. Influenza Virus Infection in Humans (2014).
Available at: https://www.who.int/influenza/human_animal_interface/virology_
laboratories_and_vaccines/influenza_virus_infections_humans_feb14.pdf?ua=1.
2. Petrova VN, Russell CA. The Evolution of Seasonal Influenza Viruses. Nat
Rev Microbiol (2018) 16(1):47–60. doi: 10.1038/nrmicro.2017.118
3. Hause BM, Collin EA, Liu R, Huang B, Sheng Z, Lu W, et al. Characterization
of a Novel Influenza Virus in Cattle and Swine: Proposal for a New Genus in
the Orthomyxoviridae Family. mBio (2014) 5(2):1–10. doi: 10.1128/
mBio.00031-144. Tan J, Asthagiri Arunkumar G, Krammer F. Universal Influenza Virus
Vaccines and Therapeutics: Where Do We Stand With Influenza B Virus?
Curr Opin Immunol (2018) 53:45–50. doi: 10.1016/j.coi.2018.04.002
5. Osterhaus AD, Rimmelzwaan GF, Martina BE, Bestebroer TM, Fouchier
RAM. Influenza B Virus in Seals. Sci (New York NY) (2000) 288(5468):1051 –
3. doi: 10.1126/science.288.5468.1051
6. Ran Z, Shen H, Lang Y, Kolb EA, Turan N, Zhu L, et al. Domestic Pigs are
Susceptible to Infection With Influenza B Viruses. J Virol (2015) 89(9):4818.
doi: 10.1128/JVI.00059-15
7. Chen R, Holmes EC. The Evolutionary Dynamics of Human Influenza B
Virus. J Mol Evol (2008) 66(6):655–63. doi: 10.1007/s00239-008-9119-zMay 2021 | Volume 12 | Article 661379
Ferrara et al. Influenza B Pseudotypes8. Rota PA, Wallis TR, HarmonMW, Rota JS, Kendal AP, Nerome K. Cocirculation
of Two Distinct Evolutionary Lineages of Influenza Type B Virus Since 1983.
Virology (1990) 175(1):59–68. doi: 10.1016/0042-6822(90)90186-U
9. Caini S, Kusznierz G, Garate VV, Wangchuk S, Thapa B, de Paula Júnior FJ,
et al. The Epidemiological Signature of Influenza B Virus and Its B/Victoria
and B/Yamagata Lineages in the 21st Century. PloS One (2019) 14(9):
e0222381–e. doi: 10.1371/journal.pone.0222381
10. Skehel JJ, Wiley DC. Receptor Binding and Membrane Fusion in Virus Entry:
The Influenza Hemagglutinin. Annu Rev Biochem (2000) 69(1):531–69. doi:
10.1146/annurev.biochem.69.1.531
11. Wiley DC, Skehel JJ. The Structure and Function of the Hemagglutinin
Membrane Glycoprotein of Influenza Virus. Annu Rev Biochem (1987) 56
(1):365–94. doi: 10.1146/annurev.bi.56.070187.002053
12. Varki A. Diversity in the Sialic Acids. Glycobiology (1992) 2(1):25–40. doi:
10.1093/glycob/2.1.25
13. Chernomordik LV, Frolov VA, Leikina E, Bronk P, Zimmerberg J. The
Pathway of Membrane Fusion Catalyzed by Influenza Hemagglutinin:
Restriction of Lipids, Hemifusion, and Lipidic Fusion Pore Formation.
J Cell Biol (1998) 140(6):1369–82. doi: 10.1083/jcb.140.6.1369
14. Garten W, Klenk H. Cleavage Activation of the Influenza Virus
Hemagglutinin and Its Role in Pathogenesis. .Monogr Virol (2008) 27:156–
67. doi: 10.1159/000151618
15. Laporte M, Stevaert A, Raeymaekers V, Boogaerts T, Nehlmeier I, Chiu W,
et al. Hemagglutinin Cleavability, Acid-Stability and Temperature
Dependence Optimize Influenza B Virus for Replication in Human
Airways. J Virol (2019) 94(1):JVI.01430–19. doi: 10.1128/JVI.01430-19
16. Wang Y-F, Chang C-F, Chi C-Y, Wang H-C, Wang J-R, Su I-J.
Characterization of Glycan Binding Specificities of Influenza B Viruses
With Correlation With Hemagglutinin Genotypes and Clinical Features.
J Med Virol (2012) 84(4):679–85. doi: 10.1002/jmv.23219
17. Klenk H-D, Garten W. Host Cell Proteases Controlling Virus Pathogenicity.
Trends Microbiol (1994) 2(2):39–43. doi: 10.1016/0966-842X(94)90123-6
18. Glezen WP, Schmier JK, Kuehn CM, Ryan KJ, Oxford J. The Burden of
Influenza B: A Structured Literature Review. Am J Public Health (2013) 103
(3):e43–51. doi: 10.2105/AJPH.2012.301137
19. Dolin R. The Quadrivalent Approach to Influenza Vaccination. J Infect Dis
(2013) 208(4):539–40. doi: 10.1093/infdis/jit264
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